News + Resources

Keep up with the latest

Featured

This Scientist Is Building Custom Gene-Editing Tools

This Scientist Is Building Custom Gene-Editing Tools

Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025

November 17, 2025

Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025

November 17, 2025

Epigenetic editors are a gentler form of gene editing

February 24, 2025

The Economist

Epigenetic editors are a gentler form of gene editing

February 24, 2025

CRISPR 2.0, the Next Generation

June 21, 2024

Aspen Ideas: Health

CRISPR 2.0, the Next Generation

June 21, 2024

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

TEDxBerkeley

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

All Stories

All
News
Press Releases
News

BioSpace 40 Under 40

October 7, 2025

BioSpace

Read Now
News

Treating High Cholesterol Could Become A One-And-Done Treatment

September 23, 2025

Forbes

Read Now
News

Getting to the Heart of CRISPR-Based Therapies

July 22, 2025

The Scientist

Read Now
News

Advancing CRISPR Cures Requires Cross-Sector Collaboration

June 13, 2025

Genetic Engineering & Biotechnology News

Read Now
News

U.S. Innovation, Strategy Needed to Counter China’s Rise in Biotech

May 29, 2025

The Wall Street Journal

Read Now
News

Heart Disease Could Be a Goner When These New Drugs Arrive

May 23, 2025

Barron's

Read Now
Press release

Scribe Therapeutics Presents Late-Breaking Preclinical Data Supporting STX-1150, a Clinical-Stage Epigenetic Silencing Therapy Designed to Achieve Years of LDL-C Lowering After a Single Dose

May 28, 2026

Read Now
Press release

Scribe Therapeutics Achieves Regulatory Clearance to Initiate First-in-Human Clinical Study of STX-1150 for LDL-C Reduction

May 21, 2026

Read Now
Press release

Scribe Therapeutics Reports Preclinical Data at ASGCT 2026 Demonstrating Enhanced Potency and Specificity of Engineered CRISPR Technologies for Epigenetic Silencing and Gene Editing

May 18, 2026

Read Now
Press release

Scribe Therapeutics to Highlight Engineered CRISPR Platform Advances and Lead Cardiometabolic Pipeline at ASGCT and EAS Congress 2026

April 30, 2026

Read Now
Press release

Scribe Therapeutics Achieves Second Success Milestone for In Vivo Program in Collaboration with Eli Lilly and Company

February 17, 2026

Read Now
Press release

Scribe Therapeutics Projected to Enter the Clinic in Mid-2026 with STX-1150, a PCSK9-targeting CRISPR Epigenetic Silencing Therapy for Durable LDL-C Reduction

January 20, 2026

Read Now

Publications and presentations